E-LIB Suche - Ergebnisse für: Nishimura, Jun-ichi

1

Moving toward Individual Treatment Goals with Pegcetacoplan..:

Szer, Jeff ; Panse, Jens ; Kulasekararaj, Austin...
International Journal of Molecular Sciences. 25 (2024) 16 - p. 8591 , 2024

Link: https://doi.org/10.3390/..

2

Long-term efficacy and safety of continued complement C1s i..:

Röth, Alexander ; Berentsen, Sigbjørn ; Barcellini, Wilma...
eClinicalMedicine. 74 (2024) - p. 102733 , 2024

Link: https://doi.org/10.1016/..

3

Addition of danicopan to ravulizumab or eculizumab in patie..:

Lee, Jong Wook ; Griffin, Morag ; Kim, Jin Seok...
The Lancet Haematology. 10 (2023) 12 - p. e955-e965 , 2023

Link: https://doi.org/10.1016/..

4

P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S I..:

Röth, Alexander ; Berentsen, Sigbjørn ; Barcellini, Wilma...
HemaSphere. 7 (2023) S3 - p. e83270db , 2023

Link: https://doi.org/10.1097/..

5

26 Sustained complement C1s inhibition with sutimlimab in p..:

Röth, Alexander ; Berentsen, Sigbjørn ; Barcellini, Wilma...
Immunobiology. 228 (2023) 5 - p. 152483 , 2023

Link: https://doi.org/10.1016/..

6

S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS ..:

Röth, Alexander ; He, Guangsheng ; Brodsky, Andres...
HemaSphere. 7 (2023) S3 - p. e72750f1 , 2023

Link: https://doi.org/10.1097/..

7

Real-world safety profile of eculizumab in patients with pa..:

Nishimura, Jun-ichi ; Kawaguchi, Tatsuya ; Ito, Shuichi...
International Journal of Hematology. , 2023

Link: https://doi.org/10.1007/..

8

P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBIT..:

Kulasekararaj, Austin ; Brodsky, Robert ; Griffin, Morag...
HemaSphere. 7 (2023) S3 - p. e6327336 , 2023

Link: https://doi.org/10.1097/..

9

P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATI..:

Röth, Alexander ; Berentsen, Sigbjørn ; Barcellini, Wilma...
HemaSphere. 7 (2023) S3 - p. e3331235 , 2023

Link: https://doi.org/10.1097/..

10

P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PARO..:

Szer, Jeff ; Panse, Jens ; Kulasekararaj, Austin...
HemaSphere. 7 (2023) S3 - p. e58190a6 , 2023

Link: https://doi.org/10.1097/..

11

Interim analysis of post-marketing surveillance of ravulizu..:

Usuki, Kensuke ; Ikezoe, Takayuki ; Ishiyama, Ken...
International Journal of Hematology. 118 (2023) 3 - p. 311-322 , 2023

Link: https://doi.org/10.1007/..

12

Ravulizumab is a Suitable Long-Term Treatment Option for Pa..:

Kulasekararaj, Austin G. ; Griffin, Morag ; Langemeijer, Saskia...
Future Rare Diseases. 3 (2023) 2 - p. , 2023

Link: https://doi.org/10.2217/..

13

Tesidolumab (LFG316) for treatment of C5-variant patients w..:

Nishimura, Jun-ichi ; Ando, Kiyoshi ; Masuko, Masayoshi...
Haematologica. 107 (2022) 6 - p. 1483-1488 , 2022

Link: https://doi.org/10.3324/..

14

Sutimlimab in patients with cold agglutinin disease: result..:

Röth, Alexander ; Berentsen, Sigbjørn ; Barcellini, Wilma...
Blood. 140 (2022) 9 - p. 980-991 , 2022

Link: https://doi.org/10.1182/..

15

The role of the alternative pathway in paroxysmal nocturnal..:

Lee, Jong Wook ; Brodsky, Robert A. ; Nishimura, Jun-Ichi.
Expert Review of Clinical Pharmacology. 15 (2022) 7 - p. 851-861 , 2022

Link: https://doi.org/10.1080/..